Life Science Leader Blogs

  1. When Will Biopharma Be Back In The Office? 9/20/2021

    Three biopharmaceutical executives discuss plans around their company getting back to in-office operations.

  2. Mental Wellness — The Next Big Thing 7/30/2021

    Recent events of female athletes expressing the need to focus on their mental health seems to point toward mental wellness being one of the next big things, along with women leaders being willing to "rewrite the rules."

  3. How Has The Pandemic Impacted You — And Your People? 4/6/2021

    Disruption of life routines by COVID-19 provide a CNS opportunity on multiple fronts. 

  4. Is Biopharma's Reputation Back? 3/26/2021

    While biopharma's response to COVID-19 has started to turnaround the industry's sagging reputation, one successful response to one crisis does not a reputation save.

  5. Are We On The Precipice Of Unprecedented Collaboration In Biopharma? 1/28/2021

    The recent announcement of Sanofi agreeing to help produce Pfizer's COVID-19 vaccine could represent biopharma's entry into a period of unprecedented collaboration.

  6. Let’s Talk About JPM 2021 1/19/2021

    Rob Wright, chief editor of Life Science Leader, shares thoughts on attending the 39th Annual J.P. Morgan Healthcare Conference (JPM) which was 100% virtual this year.

  7. What Went Right In 2020? My Top 5 List 1/5/2021

    Life Science Leader's Rob Wright reviews five things that went right in 2020.

  8. What Would You Do? 10/22/2020

    A call with a young reader reveals a biopharmaceutical industry mentorship opportunity beyond science.

  9. What Does Travel Look Like For You In 2021? 9/24/2020

    With the annual J.P. Morgan Healthcare conference going virtual in January of 2021, Rob Wright asks readers about their business travel plans for next year, and includes anonymized thoughts on posed questions from two Life Science Leader editorial advisory board members.

  10. It’s Time We Ready Americans For The COVID-19 Long Haul 7/15/2020

    Rob Wright issues a call to action to everyone connected to the biopharmaceutical industry, recommending they begin communicating the realities of developing and distributing a COVID-19 vaccine by the end of this year.